Cyclic ADP-ribose (cADPR) is a universal calcium messenger molecule that regulates many physiological processes. The production and degradation of cADPR are catalyzed by a family of related enzymes, including the ADP-ribosyl cyclase from Aplysia california (ADPRAC) and CD38 from human. Although ADPRC and CD38 share a common evolutionary ancestor, their enzymatic functions toward NAD and cADPR homeostasis have evolved divergently. Thus, ADPRC can only generate cADPR from NAD (cyclase), whereas CD38, in contrast, has multiple activities, i.e. in cADPR production and degradation, as well as NAD hydrolysis (NADase). In this study, we determined a number of ADPRC and CD38 structures bound with various nucleotides. From these complexes, we elucidated the structural features required for the cyclization (cyclase) reaction of ADPRC and the NADase reaction of CD38. Using the structural approach in combination with site-directed mutagenesis, we identified Phe-174 in ADPRC as a critical residue in directing the folding of the substrate during the cyclization reaction. Thus, a point mutation of Phe-174 to glycine can turn ADPRC from a cyclase toward an NADase. The equivalent residue in CD38, Thr-221, is shown to disfavor the cyclizing folding of the substrate, resulting in NADase being the dominant activity. The comprehensive structural comparison of CD38 and APDRC presented in this study thus provides insights into the structural determinants for the functional evolution from a cyclase to a hydrolase.
crystal structures of the complexes of ADPRC and CD38 bound with various catalytically revealing substrates and products ( Fig. 1, A-C) . The results identify residues Phe-174 in the cyclase and Thr-221 in CD38 as the main determinants for the cyclase and hydrolysis activities of the enzymes. All together, these structures provide insights into the structural requirements for functional evolution from a cyclase to a hydrolase.
EXPERIMENTAL PROCEDURES
Crystallization and Complex Formation-Production of recombinant CD38 and Aplysia ADPRC were as described previously (17, 18) . All crystals were obtained by the hanging drop vapor diffusion technique. Crystallization of ADPRC was done by mixing 1 l of protein sample with 1 l of precipitants (0.1 M imidazole, pH 7.5, 12-24% polyethylene glycol 4000). Dependent on polyethylene glycol 4000 concentration, wildtype ADPRC crystals can be crystallized in space group P1, P2 1 , or P6 1 , whereas E179G ADPRC mutant crystals are always in space group P2 1 . NAD was purchased from SigmaAldrich. N(2F-A)D, ara-2ЈF-NAD, and ribo-2ЈF-NAD were synthesized according to established procedures (15, 19) . N1-cIDPR was obtained by chemoenzymatic routes as illustrated (20) . The E179G ADPRC⅐NAD complex was obtained by soaking crystals with NAD (10 mM) in mother liquor containing 25% glycerol for about 2 min. The WT ADPRC⅐2F-ADPRI⅐ Nic complex was obtained by soaking WT ADPRC crystals with a solution of N(2F-A)D (33 mM) for 3 min, whereas the E179G ADPRC⅐N1-cIDPR complex was obtained by soaking mutant ADPRC crystals in 12 mM N1-cIDPR solution for 8 min. All soaking experiments were carried out at 4°C for optimal results. After soaking, crystals were immediately flash-frozen with liquid nitrogen.
Wild-type CD38 was crystallized as described previously (21) . The WT CD38⅐ara-2ЈF-ADPR and WT CD38⅐ribo-2ЈF-ADPR complexes were obtained by soaking crystals in a solution containing either 5.2 mM ara-2ЈF-NAD or 3 mM ribo-2ЈF-NAD and 100 mM MES, pH 6.0, 15% polyethylene glycol 4000, and 30% glycerol. For these two NAD analogs, covalent adducts are formed after nicotinamide cleavage, resulting in inhibition of the enzyme activity. The soaking is thus insensitive to time (1 min or several days) and temperature (4 or 24°C).
Crystallographic Data Collection and Structural Refinement-X-ray diffraction data were collected at 100 K at the Cornell High Energy Synchrotron Source (CHESS) A1 station. All data sets were processed by using the program HKL2000 suite (22) . The crystallographic statistics are listed in Table 1 . All complex structures were determined by difference Fourier calculation with the starting phases derived from the WT CD38 model (Protein Data Bank (PDB) ID: 1YH3) for CD38 complexes and WT ADPRC (PDB ID: 1BLE) for ADPRC complexes. The models for all ligands were built FIGURE 1. Schemes of cADPR formation and mechanistic analogs for substrate and product. A, the cyclization reaction producing cADPR from NAD is catalyzed by both ADPRC and CD38. The structural difference between cADPR and N1-cIDPR lies at the 6-position of purine ring (6-NH for cADPR; 6-O for N1-cIDPR). B, an analog of the substrate NAD, N(2F-A)D, is enzymatically converted to 2F-ADPR by ADPRC instead of cyclized to c(2F-A)DPR. The formation of cADPR from NAD requires the intramolecular attack of the reaction intermediate by the adenine N1 atom. The addition of a fluorine atom on the adjacent C2 atom of adenine prevents the cyclization from occurring. C, ara-2ЈF-NAD and ribo-2ЈF-NAD are analogs of NAD that inhibit the cyclization reaction by producing covalent adducts during the catalysis by CD38. Both analogs differ only in the orientation of their fluorine atoms at the 2Ј-position of the adenine ribose.
manually in O (23) based on the A weighted F o Ϫ F c difference electron density maps. For CD38 complexes, the catalytic residue Glu-226 was modeled as covalently linked to ara-2ЈF-ADPR and ribo-2ЈF-ADPR. Structure refinements for these complexes were performed using the program REFMAC5 (24) with manually modified stereochemical restraints generated from the program PRODRG (25) . TLS group refinements were introduced to model data anisotropy. Solvents were added automatically by Arp/warp (26) and manually inspected and modified in the program O. The refinement results and model statistics are also listed in Table 1 .
Site-directed Mutagenesis of ADPRC-The WT ADPRC cDNA was cloned into the pPICZaA vector (Invitrogen) and expressed in Pichia pastoris (27) . The F174G mutant was prepared from the wild-type plasmid by using a site-directed mutagenesis kit (Stratagene). The forward primer used during the PCR reaction was 5Ј-GCTTACAGGCCAGACAGTGGC-TTTGGCAAGTACGAACT-3Ј, and the reverse primer was 5Ј-AGTTCGTACTTGCCAAAGCCACTGTCTGGCCTGTA-AGC-3Ј. The bases in bold represent the changes made to code for glycine. The E179G mutant was prepared as described previously (17) . All cyclase proteins and CD38 were purified by cation exchange chromatography.
Enzyme Assays-Hydrolysis of cADPR by ADPRC. The wildtype ADPRC (5 g/ml) was incubated (10 -40 min) at room temperature with 1 mM cADPR buffered by 25 mM Tris-HCl, pH 8. The total volume of the reaction mixture was 0.1 ml, and the reaction was stopped by the addition of SDS (0.15% final concentration). The reaction products were analyzed by HPLC using an AG MP-1 column 10 ϫ 120 mm (Bio-Rad). The elution was performed using a gradient of trifluoroacetic acid at a flow rate of 3 ml/min. The results shown are mean Ϯ S.E. of four determinations.
Cyclization and hydrolysis of NAD by ADPRC. Wild-type (0.1 g/ml) or F174G (1 g/ml) ADPRC was incubated with 0.1 mM NAD in 25 mM Tris-HCl, pH 8, for various times, and the products were analyzed by HPLC as described above. The results are the mean Ϯ S.E. of four determinations.
RESULTS AND DISCUSSION
E179G ADPRC⅐NAD Complex-Wild-type ADPRC catalyzes the production of cADPR from NAD. A catalytically inactive mutant E179G ( E179G ADPRC) (17) was thus used to form a complex with NAD by soaking preformed E179G ADPRC crystals with NAD at 4°C. Due to the greatly reduced catalytic activity in the E179G ADPRC mutant (17) , NAD accumulated in the active site without being hydrolyzed. The E179G ADPRC⅐NAD complex structure was determined at 1.83 Å resolution, and the active site structure is shown in Fig. 2A . The nicotinamide moiety of NAD has H-bonding with both Glu-98 and Asn-107, and it stacks with the hydrophobic indole ring of Trp-140 in a parallel manner, thereby positioning the N-glycosidic bond into the active site for catalytic cleavage. The diphosphate group of NAD forms H-bonds with residues Arg-170, Ser-78, Phe-174, and Phe-175. These four residues, together with the Glu-98-Asn-107-Trp-140 triplet, seemingly compose a docking site for proper recognition and positioning of NAD into the active site for catalysis. Electron densities for nicotinamide, the nicotinamide ribose, and diphosphate are well defined, whereas those of the adenine terminus, however, cannot be seen because of its out-of-pocket location. It is intuitively clear that in order for the cyclization of NAD to occur, the adenine ring must fold back toward and anneal with the nicotinamide ribose. The complex shown in Fig. 2A , with the adenine ring positioned out of the active site pocket in a disordered manner, is thus not poised for the cyclization reaction, probably due to the occupation of uncleaved nicotinamide in the cyclization site.
ADPRC Favors Cyclization Reaction-To reveal the underlying mechanism for ADPRC in the cyclization reaction, we tested an NAD analog, N(2F-A)D (Fig. 1B) , for its ability to form WT ADPRC. In this analog, the addition of the fluorine atom at the 2-position of the adenine moiety apparently reduces the reactivity of the nitrogen at the 1-position, which is the site of cyclization. Consequently, N(2F-A)D is hydrolyzed by the WT ADPRC to 2F-ADPR instead of being cyclized to 2F-cADPR (15) . We determined the complex structure and refined it to 2.18 Å resolution. The electron densities clearly show two well separated species in the active site of WT ADPRC (Fig. 2B) . One is the cleaved nicotinamide, which is close to the Glu-98-Asn-107-Trp-140 triplet, and the other is a 2F-ADPR intermediate (2F-ADPRI). No electron density is between the C1Ј atom of the ribose and nicotinamide, indicating that the nicotinamide is completely cleaved from the substrate. ADPRC is thus active even in the crystalline form and able to catalyze the hydrolysis of N(2F-A)D. Although the cleaved nicotinamide is still in the active site, the adenine moiety of 2F-ADPRI in the complex formed with the wild-type cyclase is now able to partially fold back toward the active site pocket. It is unexpected for nicotinamide being trapped in the active site after its cleavage and dissociation from 2F-ADPRI. In fact, the trapped nicotinamide in the active site has close interactions with Asn-107 and Trp-140, impeding the complete folding back of the 2F-adenine for cyclization. This would allow slow hydrolysis of N(2F-A)D to 2F-ADPR, consistent with the fact that in solution, the substrate is hydrolyzed by ADPRC instead of cyclized (15) .
To find structural factors that contribute to the folding back of the adenine ring, we aligned and compared the E179G ADPRC⅐NAD complex with the WT ADPRC⅐2F-ADPRI⅐Nic complex (Fig. 2C) . The alignment shows that Phe-174 rotates its side chain by 10°to coordinate with the folding of the 2F-adenine moiety. In the WT ADPRC⅐ 2F-ADPRI⅐Nic complex, Phe-174 interacts hydrophobically with the 2F-adenine moiety, whereas no such interactions are apparent in the E179G ADPRC⅐NAD complex in which the adenine terminus is disordered (Fig. 2C ). The differences suggest that Phe-174 is likely to be important in guiding the folding of the adenine moiety and thus should contribute to the cyclization preference of ADPRC, as will be described in more detail below. Fig. 2C also shows that after the N-glycosidic bond breaks, the Glu-98-Asn-107-Trp-140 triplet appears to pull the nicotinamide away from the remaining 2F-ADPRI C1Ј atom in a dissociative manner, which can contribute to the cleavage of the N-glycosidic bond. On the other hand, the diphosphate of the substrates aligns quite well in both structures, indicating that there is only minimal movement in this portion of the molecule during the reaction. The conformational changes of the Glu-98-Asn-107-Trp-140 triplet result in a slight enlargement of the active site, which can be particularly important for the release of the cleaved nicotinamide and the subsequent entry of the adenine moiety into the active site during cyclization of NAD. The triplet thus has a similar functional role as has been described previously for the corresponding residues in CD38 (28) .
E179G ADPRC⅐N1-cIDPR Complex Reveals a Novel Binding Site-ADPRC cyclizes NAD to produce cADPR, a product that is released from the enzyme. There has been no report that ADPRC can form a complex with cADPR, nor has there been any investigation about whether it can hydrolyze cADPR. The prior effort in obtaining an ADPRC⅐cADPR complex was not successful (17) , either because the cyclase has no affinity for cADPR or because the enzyme hydrolyzes it during crystallization. We thus tested whether the cyclase can hydrolyze cADPR. This turns out to be the case, as shown in Fig. 3 . Incubation of cADPR with the ADPRC resulted in its progressive hydrolysis to ADPR, as analyzed by HPLC.
We therefore used an analog of cADPR, N1-cIDPR (20) , for complex formation with the E179G ADPRC mutant. This analog has previously been used to obtain the CD38⅐N1-cIDPR complex (28). N1-cIDPR was infused into preformed crystals of E179G ADPRC by a soaking procedure similar to that used in obtaining the CD38⅐N1-cIDPR complex. Fig. 4A shows that N1-cIDPR can indeed bind to ADPRC. The electron density unambiguously defines the entity of N1-cIDPR in a cleft close to the active site. The hypoxanthine moiety of N1-cIDPR interacts hydrophobically with the phenyl ring of Phe-174, whereas the hypoxanthine ribose 3Ј-OH group forms an H-bond with the carboxylate group of Glu-98. Although both residues (Phe-174 and Glu-98) are part of the pocket, the N1-cIDPR binding site is away from the active site, as shown in Fig. 4B . A number of bound water molecules are observed to be recruited for N1-cIDPR binding.
Although N1-cIDPR can bind to the active site ADPRC, the binding is different from that in CD38 shown previously (28) . Fig. 4C compares E179G ADPRC⅐N1-cIDPR and E226Q CD38⅐N1- cIDPR. It can be seen that N1-cIDPR binds to ADPRC in an upsidedown and left-right orientation as compared with its position in CD38. In ADPRC, the adenine ribose of N1-cIDPR points to the catalytic residue Glu-179, whereas in CD38, it is the northern ribose that points to the catalytic residue Glu-226. Because of the hydrophobic interaction between Phe-174 and the hypoxanthine moiety, N1-cIDPR does not interact with residues Arg-170, Ser-78, and Phe-175. However, in the E179G ADPRC⅐NAD complex, these residues are involved in substrate recognition and binding ( Fig.  2A) . We have also determined the WT ADPRC⅐N1-cIDPR complex and observed the same binding of N1-cI-DPR as in the E179G mutant (data not shown), indicating that, unlike the linear NAD⅐ADPRC complex described above, the catalytic residue Glu-179 has minimal ability to recruit N1-cIDPR into the active site.
Another notable difference between the N1-cIDPR binding sites in CD38 and ADPRC is that the former is much deeper into the active site pocket (Fig. 4C) . This is most likely because of the strong hydrophobic stacking between Phe-174 in ADPRC with the hypoxanthine moiety of N1-cIDPR, preventing the cyclic nucleotide from entering deeper into the pocket. In CD38, the residue corresponding to Phe-174 (in ADPRC) is Thr-221. The absence of the benzyl ring on Thr-221 may greatly reduce the stacking interaction and allows N1-cIDPR to reach deeper into the active site in both the wild-type CD38 and its mutant E226Q CD38 (28) (Fig. 4C) . CD38 Favors the NAD Hydrolyzation Reaction-The structural results described above indicate the preference of ADPRC for the cyclization reaction. It is then of interest to determine the structural mechanism of the preference of CD38 in the hydrolyzation reaction. We thus tested two substrate analogs of NAD, ara-2ЈF-NAD and ribo-2ЈF-NAD. We have previously shown that ara-2ЈF-NMN forms a covalent CD38 with a cADPR analog, N1-cIDPR. A, the structure of the binding site of the E179G ADPRC⅐N1-cIDPR complex. The color scheme for residues involved in N1-cIDPR binding is the same as in Fig. 2A . Residues Glu-98 and Phe-174 have polar and non-polar interactions with N1-cIDPR, respectively, and play a major role in N1-cIDPR binding. Red spheres are water molecules that participate in N1-cIDPR binding through hydrogen-bonding interactions. Electron density for N1-cIDPR is shown as gray isomesh contoured at 2.5 . B, surface representation, colored in gray, of the N1-cIDPR binding site with N1-cIDPR (sticks) and water molecules (spheres) in the binding cleft. C, N1-cIDPR binds to a site in ADPRC that is different from CD38. In CD38 (aquamarine), N1-cIDPR binds deep into the active site, whereas in ADPRC, the site is farther away from the catalytic residue (6.1Å) and in an upside-down and left-right conformation.
intermediate with CD38 (29) . This is also true for the ara-2ЈF-NAD, as shown in Fig. 5A . Soaking CD38 crystals with the substrate resulted in the cleavage of the nicotinamide, and the remaining nucleotide formed a covalent adduct between the nicotinamide ribose C1Ј and the carboxylate group of the catalytic residue, Glu-226, as clearly shown by the observed electron densities (Fig. 5A) . The formation of the covalent adduct fixes one end at the C1Ј position of the nicotinamide ribose and allows structural evaluation of the folding ability of the other end, the adenine terminus, which is observed to fold back and enter the active site (Fig. 5A ). This is similar to that described above in the 2F-ADPR⅐ADPRC complex (Fig.  2B) . Two water molecules are close to the C1Ј carbon, but neither of them can hydrolyze the covalent adduct, indicating that the linkage is stable and resistant to further hydrolysis by the bound water. The diphosphate group forms a number of H-bonds with Trp-125, Ser-126, Arg-127, and Phe-222. There is an H-bond between the adenine ribose and Thr-221, suggesting a role of this residue in stabilizing and guiding the adenine ring terminus into the active site. Although the adenine ring is folded back into the active site, its conformation does not favor the cyclizing N-1-C1Ј linkage. The reason is that, in the conformation shown in Fig. 5A , it is the N-7 atom, not the N-1, on adenine moiety that is close to the C1Ј of the terminal ribose.
The adenine moiety has hydrophobic interaction with Trp-189 and H-bonds with Glu-146, Asp-155, as well as nearby bound water. The presence of trapped water in the active site shows that water enters the active site more readily than the adenine ring, which needs to fold back to form cADPR. This is consistent with the fact that CD38 produces mostly ADPR from NAD through a hydrolyzation reaction, instead of cADPR through a cyclization reaction. CD38⅐ara-2ЈF-ADPR complex. The active site residues are shown as sticks. Covalent adduct ara-2ЈF-ADPR is also shown as sticks with its carbon atoms in green. Weighted 2F o Ϫ F c omit electron density is shown as gray isomesh contoured at 1.2 covering both ara-2ЈF-ADPR and Glu-226. Two water molecules trapped in the active site are shown as red spheres. After cleavage and removal of nicotinamide from substrate ara-2ЈF-NAD, the remaining part forms a covalent adduct with the catalytic residue Glu-226, resulting in inhibition of the enzyme. After the release of the nicotinamide moiety, the adenine ring terminus can partially enter the active site, but it cannot cyclize with the terminal ribose because of the stability of the covalent intermediate and the incorrect orientation of the adenine ring, with the N1-cyclizing site pointing away. Two water molecules are present but cannot hydrolyze the intermediate, indicating its stability. B, the active site structure of the WT CD38⅐ribo-2ЈF-ADPR complex. The drawing and color scheme are the same as in A. C, structural comparison of ara-2ЈF-ADPR (green carbon) and ribo-2ЈF-ADPR (yellow carbon) complexed with CD38. The alignment shows that after the release of the nicotinamide, the adenine moiety is not able to either enter the catalytic site or enter in a wrong orientation. Both conformations of the adenine moiety favor the hydrolyzation reaction to take place. WT ADPRC⅐2F-ADPR⅐Nic complex is superimposed with the WT CD38⅐ribo-2ЈF-ADPR complex. In both complexes, the first step of the reaction, e.g. the N-glycosidic bond cleavage, has finished. The comparison shows structural differences in the positioning of some key resides in their active sites, including Glu-98 (Glu-146 in CD38), Asn-107 (Asp-155 in CD38), Trp-140 (Trp-189 in CD38), and Phe-174 (Thr-221 in CD38). Of particular interest is Phe-174 in ADPRC, which is more bulky than the corresponding residue, Thr-221, in CD38 and appears to have hydrophobic interaction with Trp-140. More importantly, Phe-174 in the WT ADPRC⅐2F-ADPR⅐Nic complex also shows hydrophobic interaction with the 2F-adenine moiety of 2F-ADPR, which is likely to be important in guiding the folding of adenine ring into the active site. Indeed, when comparing the complexes of unfolded and folded substrates, as shown in Fig.  2C , the phenyl ring of the Phe-174 residue is shown to rotate 10°t o promote the folding of the adenine moiety. A corollary of this interpretation is that when changing Phe-174 to a less bulky and/or hydrophobic residue, the cyclization activity of the enzyme would be reduced, whereas its hydrolytic activity should be enhanced. This is the case in CD38, which has a less hydrophobic threonine at the corresponding position and thus high hydrolytic activity. To further confirm the importance of Phe-174 in the cyclization reaction, we removed its hydrophobic character by mutating the residue to a glycine. As shown in Fig. 6B , indeed, the mutation bestows the F174G mutant with high NAD-hydrolyzing activity, producing about 30% of its catalytic products as ADPR, whereas none is observed with the wild-type ADPRC.
